A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans
- 1 December 1999
- journal article
- Published by Elsevier in Experimental Hematology
- Vol. 27 (12), 1724-1734
- https://doi.org/10.1016/s0301-472x(99)00112-5
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- A cytokinetic model describes the granulopoietic effects of r-metHuG-CSF-SD/01 (SD/01) and the homeostatic regulation of SD/01 clearance in normal volunteersClinical Pharmacology & Therapeutics, 1999
- An Analysis of the Effects of Combined Treatment with rmGM‐CSF and PEG‐rHuMGDF in Murine Bone Marrow Transplant RecipientsThe International Journal of Cell Cloning, 1997
- Mobilisation kinetics of primitive haemopoietic cells following G-CSF with or without chemotherapy for advanced breast cancerAnnals of Oncology, 1996
- Filgrastim (r-metHuG-CSF): the first 10 yearsBlood, 1996
- Megakaryocyte growth and development factor accelerates platelet recovery in peripheral blood progenitor cell transplant recipientsBlood, 1996
- Haemopoietic progenitor and myeloid cell kinetics in humans treated with interleukin-3 and granulocyte/macrophage colony-stimulating factor in combinationInternational Journal of Cancer, 1994
- Myeloid cell kinetics in mice treated with recombinant interleukin-3, granulocyte colony-stimulating factor (CSF), or granulocyte-macrophage CSF in vivoBlood, 1991
- Transplantation potential of peripheral blood stem cells induced by granulocyte colony-stimulating factorBlood, 1990
- A comparison of hematopoiesis in normal and splenectomized mice treated with granulocyte colony-stimulating factorBlood, 1990
- Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancerBritish Journal of Cancer, 1987